The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark L. Pacala Acquires 90,562 Shares

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Mark L. Pacala bought 90,562 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $1.04 per share, for a total transaction of $94,184.48. Following the transaction, the director now owns 224,971 shares in the company, valued at $233,969.84. The trade was a 67.38 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Oncology Institute Stock Up 10.5 %

TOI traded up $0.12 during trading hours on Tuesday, hitting $1.26. 1,194,217 shares of the company's stock were exchanged, compared to its average volume of 706,440. The stock has a market cap of $95.20 million, a price-to-earnings ratio of -1.62 and a beta of 0.41. The Oncology Institute, Inc. has a 1-year low of $0.13 and a 1-year high of $1.63. The stock's 50-day moving average is $0.88 and its two-hundred day moving average is $0.49. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91.

Oncology Institute (NASDAQ:TOI - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%. The company had revenue of $100.27 million during the quarter, compared to the consensus estimate of $109.15 million.

Remove Ads

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Tiff Advisory Services LLC grew its stake in shares of Oncology Institute by 13.2% in the fourth quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company's stock valued at $921,000 after buying an additional 346,256 shares in the last quarter. FreeGulliver LLC lifted its stake in Oncology Institute by 219.3% in the fourth quarter. FreeGulliver LLC now owns 600,747 shares of the company's stock valued at $186,000 after acquiring an additional 412,578 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Oncology Institute by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after acquiring an additional 12,000 shares during the period. Virtu Financial LLC acquired a new position in shares of Oncology Institute during the 4th quarter worth about $41,000. Finally, Jane Street Group LLC raised its holdings in shares of Oncology Institute by 613.6% in the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock valued at $39,000 after purchasing an additional 109,769 shares during the period. Institutional investors and hedge funds own 36.86% of the company's stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.